ldx
- Home
- ldx
Lumos Diagnostics receives regulatory approval for rapid test in Brazil
Rapid antigen tests (or lack thereof) have dominated the headlines for months now. Turning your kitchen counter into a mini pathology lab is now an essential ritual in determining if it’s the sniffles or the dreaded ‘c word’. Specialists in rapid point-of-care diagnostic technologies, Lumos Diagnostics (ASX: LDX) have been working on a useful test,
Read MorePublic
RATs – The ASX-listed companies manufacturing Rapid Antigen Tests that you cannot buy
With ‘Rapid Antigen Test’ having only taken several days to likely be one of the most commonly used words of 2022, everyone is looking for them but demand is monumentally outweighing supply. With their surge in use, it may only be a matter of time until Australian regulators fast-track approval of more RAT manufacturers with
Read MorePublic
Lumos receives first orders from Canada for rapid COVID test kits following regulatory approval
Having secured approval from regulators in Canada last month, Lumos Diagnostics (ASX: LDX) is set to dispatch the first orders of their rapid antigen test kit to the Maple nation with the initial orders valued at USD $250,000 (AUD $350,000). The orders are for Lumos’ CoviDx™ test kit which will enable qualified healthcare providers to
Read MorePublic
IPO Watch: Lumos to accelerate decentralised healthcare diagnostics with $187m float
With ever increasing bodies of medical research and demand for early disease detection climbing, it’s high time that we rethink diagnostic testing. The trend of having to wait three days to see if your pee is free of nasties is fraught with administration challenges and can delay treatment. Spend time in any medical establishment and
Read MorePublic